Shilpa Medicare Limited announced its financial results for the second quarter of Fiscal Year 2027 (2QFY27), reporting its highest-ever quarterly revenue and EBITDA. The company achieved a total income of INR 538 crore, marking a 45% YoY growth. EBITDA stood at INR 151 crore, a 37% YoY increase, with healthy EBITDA margins maintained at 28%. All three business verticals contributed significantly to this performance.
Record Financial Performance in 2Q FY27
Shilpa Medicare Limited has achieved a significant milestone by reporting its highest-ever quarterly revenue and EBITDA for the second quarter of Fiscal Year 2027 (2QFY27), ending September 30, 2026. The company’s total income reached INR 538 crore, representing a substantial 45% year-over-year (YoY) increase and a 15% sequential growth from the previous quarter. This robust revenue performance was driven by broad-based growth across all its key business verticals.
EBITDA and Profitability Highlights
Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for 2QFY27 stood at INR 151 crore, up 37% YoY and 9% QoQ. The company successfully maintained healthy EBITDA margins at 28%, demonstrating efficient operational management and profitability. Profit After Tax (PAT) also saw a significant increase, growing by approximately 80% YoY to INR 79 crore.
Revenue Contribution by Segments
The API segment continues to be the largest contributor to revenue, accounting for 47% in 2QFY27, followed by Formulations at 39%, and Biologics at 12%. The company highlighted that its API division recorded its highest-ever quarterly revenue, underscoring the breadth and resilience of its business. Formulations and Biologics also demonstrated strong performance, contributing meaningfully to the overall financial results.
First Half FY27 Performance
For the first half of Fiscal Year 2027 (1HFY27), Shilpa Medicare reported a total income of INR 1,007 crore, crossing the INR 1,000 crore mark for the first time in a half-year. This represents a 44% YoY growth. EBITDA for 1HFY27 grew by 40% YoY to INR 290 crore, with margins remaining stable at around 29%. PAT nearly doubled, increasing by 98% YoY to INR 180 crore, with PAT margins expanding to 18%.
Strategic Outlook and Growth Drivers
The management commentary emphasizes a strategic focus on innovation-led differentiation and high-value partnerships. The company is expanding its novel FDF portfolio with niche launches planned, which are expected to contribute to growth. The partnership with Orion Corporation for the Nivolumab biosimilar in Europe is highlighted as a key development reinforcing Shilpa’s position in complex therapies. The company also noted improvements in capital efficiency and its CRISIL ESG score, positioning it well for a stronger FY27.
Source: BSE
